Press releases

Company will also present results from the ARRIVE diabetic subset analysis, the ATLAS Workhorse and Direct Stenting trials and ATLAS data on small vessels and long lesions

The recent turmoil in the financial markets and bankruptcy of Lehman Brothers triggered automatic share selling

Company to discuss these and other issues on its third quarter earnings call on October 23 at 8:00 a.m.

PERSEUS clinical program to evaluate TAXUS® Element™ Platinum Chromium Stent

Judgment against Company entered in a patent case filed in 1997; Company to appeal

Company also announces FDA approval of TAXUS® Express2™ Stent System for treatment of in-stent restenosis

A live webcast and replay of the September 25 session will be available

Boston Scientific Corporation (NYSE: BSX) announced today a decision by the United States District Court in Delaware. The case involves a patent...

A live webcast and replay of the Tuesday, September 16 session will be available

Company announced positive one-year results from the world's largest post-approval, prospective registry for a single drug-eluting stent (DES)

Overall results demonstrated no statistically significant differences between PCI and CABG in rates of death or myocardial infarction (MI)

Boston Scientific obligation reduced from $250 to $19 million; Company to appeal remaining award

Company to present data from landmark SYNTAX clinical trial

"We were pleased with the quarter, especially with our expense management and working capital initiatives,” said CEO Jim Tobin.

Boston Scientific only company to offer choice of two distinct drugs on separate drug-eluting stent platforms

A live webcast and replay of the July 22 conference call will be available

Legislation would help service veterans and the active armed forces better manage the challenges of chronic pain

Transactions further Company's plans to focus on core businesses and increase shareholder value

Fitch also reaffirmed the Company's long-term credit rating of BB+

A live webcast and replay of the June 11 session will be available

Company announces management changes and further organizational consolidation

Environmentally focused improvements are hallmark of renovations to Endosurgery headquarters

Transaction follows the definitive agreement announced on April 16

Boston Scientific Corporation (NYSE: BSX) today announced that a U.S. District Court jury in Marshall, Texas has reached a verdict in a patent...

Boston Scientific Corporation (NYSE: BSX) today announced results from an international, multi-center patient registry documenting...

Boston Scientific Corporation (NYSE: BSX) today announced the launch of its FilterWire EZ™ Embolic Protection System in a new 2.25 - 3.5 mm size,...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its ACUITY® Spiral left ventricular...

Boston Scientific Corporation (NYSE: BSX) today announced that results from an international, multi-center patient registry documenting the safety...

Boston Scientific Corporation (NYSE: BSX) today announced a new clinical science initiative, ALTITUDE, which will analyze data(1) from the...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its COGNIS™ cardiac...

Boston Scientific Corporation (NYSE: BSX) today announced results from an analysis of nearly 7,500 patients from its TAXUS...

Boston Scientific Corporation (NYSE: BSX) today welcomed two-year results from the SPIRIT III clinical trial, which continue to...

Boston Scientific Corporation (NYSE: BSX) and the International Diabetes Federation (IDF) today announced that Boston...

Boston Scientific Corporation (NYSE: BSX) announced today that the Canadian Federal Court has issued judgment in a lawsuit in which Johnson & Johnson...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) approval of its ALTRUA™ family of pacemakers....

Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and market launch of its ALTRUA™ family of pacemakers. ALTRUA is Boston...

Boston Scientific Corporation (NYSE: BSX) announced today that a World Intellectual Property Organization (WIPO) arbitration panel has issued its...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Deutsche Bank Health Care Conference, which is being held May 5-7 in...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Unplugged Conference, which is being...

Boston Scientific Corporation (NYSE: BSX) today announced completion of enrollment in the Multicenter Automatic Defibrillator Implantation Trial...

Boston Scientific Corporation (NYSE: BSX) today announced that it has been named U.S. Healthcare Supplier of the Year in the GHXcellence Awards...

Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2008, as well as guidance for...

Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval for the sale of its TAXUS® Liberte® paclitaxel-eluting...

Boston Scientific Corporation (NYSE: BSX) and CryoCor, Inc. (NASDAQ: CRYO) today announced the signing of a definitive...

Boston Scientific Corporation (NYSE: BSX) and Surgi-Vision, Inc., a privately held company, today announced a licensing and...

Boston Scientific Corporation (NYSE: BSX) today announced Japanese Ministry of Health, Labor and Welfare (MHLW) approval of its ACUITY® Steerable...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the first quarter ended March 31,...

Boston Scientific Corporation (NYSE: BSX) today announced the appointment of Timothy Pratt as its new General Counsel. Pratt is a nationally...

Boston Scientific Corporation (NYSE: BSX) today announced that United States District Judge Sarah Evans Barker, Indianapolis, dismissed...

Boston Scientific Corporation (NYSE: BSX) today announced results from a pooled analysis of patients from its TAXUS IV and TAXUS...